ReviewNature microbiology2022
COVID-19-associated fungal infections.
Review in Nature microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 269 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
269 citing papers in PubMed, 2 syntheses or guidelines pooled it, 454 citations in OpenAlex.
- Incidence, mortality and risk factors of invasive pulmonary aspergillosis in critically ill patients during the COVID-19 era: a global systematic review and meta-analysis.Annals of clinical microbiology and antimicrobials · 2026Pooled it
- Candidemia Following Severe COVID-19 in Hospitalised and Critical Ill Patients: A Systematic Review and Meta-Analysis.Mycoses · 2024Pooled it
- Clinical Characteristics, Management and Outcomes of Nonintensive Care Unit Candidemia: Subanalysis of the ECMMOpen forum infectious diseases · 2026Trial
- Pathogen-Specific PET Imaging of Pulmonary Infection Using [Chemical & biomedical imaging · 2026Article
- WHO Critical Priority Fungi: A Comprehensive Review of Antifungal Resistance, Emerging Therapeutic Strategies, and the Potential of Antifungal Peptides.International journal of molecular sciences · 2026Review
- COVID-19-Associated Fungal Co-Infections: Pathogenesis, Diagnostics, Biomarkers, and Therapeutic Strategies.Journal of clinical medicine · 2026Review
- Article
- Evolution of Candidaemia and azole resistance in Italy: A multicentre retrospective study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- SARS‑CoV‑2 Associated Shifts in the Upper Respiratory Tract Mycobiome in Non-hospitalized Cases.Mycopathologia · 2026Article
- Candida glabrata Emerges as the Most Common Cause of Candidemia: Analysis of a Large Hospital-Based Database, United States, 2016-2024.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Delayed intubation and 60-day mortality in severe COVID-19-associated acute respiratory failure in an emulated target trial using the OUTCOMEREA network.Scientific reports · 2026Article
- Treatment Monitoring and Outcome Prediction in Invasive Aspergillosis Using Immunologic Markers.The Journal of infectious diseases · 2026Article
- Ten-Year Trends in Candidemia at a Tertiary-Care Hospital in Spain (2015-2024): Epidemiological Shifts, Diagnostic Acceleration, and Impact of Antifungal Stewardship in the COVID-19 and Post-Pandemic Era.Journal of fungi (Basel, Switzerland) · 2026Article
- Clinical Features, Treatment, and Outcomes of Mucormycosis: A Retrospective Analysis of 13 Cases from a Single Center in Turkey (2015-2025).Tropical medicine and infectious disease · 2026Article
- Emerging evidence for a multitude of mechanisms and factors that determine amphotericin B resistance in pathogenic fungi.Cell surface (Amsterdam, Netherlands) · 2026Review
- Biofilm formation efficiency by Candida species isolated from gastric mucosa of intragastric balloon patient under extremely low pH.Folia microbiologica · 2026Article
- Review of the Microbial Spectrum of Mixed Respiratory Fungal Infections.Journal of epidemiology and global health · 2026Review
- β-Glucan chitosan particle provides cross-protection against multi-drug-resistant Candida auris.NPJ vaccines · 2026Article
- Review
- Risk factors for intensive care unit coronavirus disease 2019 pneumonia-associated invasive fungal infections: a Bayesian evidence synthesis integrating external and real-world data.Virology journal · 2026Article
209 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 6 countries.
Funding
Abstract
Coronavirus disease 2019 (COVID-19)-associated invasive fungal infections are an important complication in a substantial number of critically ill, hospitalized patients with COVID-19. Three groups of fungal pathogens cause co-infections in COVID-19: Aspergillus, Mucorales and Candida species, including Candida auris. Here we review the incidence of COVID-19-associated invasive fungal infections caused by these fungi in low-, middle- and high-income countries. By evaluating the epidemiology, clinical risk factors, predisposing features of the host environment and immunological mechanisms that underlie the pathogenesis of these co-infections, we set the scene for future research and development of clinical guidance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.